



What is the superior surgical strategy for bi-level cervical spondylosis-anterior cervical disc replacement or anterior cervical decompression and fusion?

A meta-analysis from 11 studies

He Zhao, MD^a, Li-Jun Duan, MD^b, Yu-Shan Gao, MD^c, Yong-Dong Yang, MD^a, Xiang-Sheng Tang, MD^d, Ding-Yan Zhao, MD^a, Yang Xiong, MD^a, Zhen-Guo Hu, MD^a, Chuan-Hong Li, MD^a, Xing Yu, MD^{a,*}

Abstract

Background: Nowadays, anterior cervical artificial disc replacement (ACDR) has achieved favorable outcomes in treatment for patients with single-level cervical spondylosis. However, It is still controversial that whether or not it will become a potent therapeutic alternation in treating 2 contiguous levels cervical spondylosis compared with anterior cervical decompression and fusion (ACDF). Therefore, we conducted a systematic review and meta-analysis to compare the efficacy and safety of ACDR and ACDF in patients with 2 contiguous levels cervical spondylosis.

Methods: According to the computer-based online search, PubMed, Embase, Web of Science, and Cochrane Library for articles published before July 1, 2017 were searched. The following outcome measures were extracted: neck disability index (NDI), visual analog scale (VAS) neck, VAS arm, Short Form (SF)-12 mental component summary (MCS), SF-12 physical component summary (PCS), overall clinical success (OCS), patient satisfaction (PS), device-related adverse event (DRAE), subsequent surgical intervention (SSI), neurological deterioration (ND), and adjacent segment degeneration (ASD). Methodological quality was evaluated independently by 2 reviewers using the Furlan for randomized controlled trial (RCT) and MINORS scale for clinical controlled trials (CCT). The chi-squared test and Higgin I^2 test were used to evaluate the heterogeneity. A P < .10 for the chi-squared test or I^2 values exceeding 50% indicated substantial heterogeneity and a random-effect model was applied; otherwise, a fixed-effect model was used. All quantitative data were analyzed by the Review Manager 5.2 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark).

Results: Nine RCTs and 2 CCT studies containing 2715 patients were included for this meta-analysis. The pooled analysis indicated that the ACDR group is superior to ACDF in NDI, VAS neck, PCS score, OCS, PS, DRAE, ASD, and SSI. However, the pooled results indicate that there was no significant difference in the ND, VAS arm and in MCS score.

Conclusions: The present meta-analysis suggests that for bi-level cervical spondylosis, ACDR appears to provide superior clinical effectiveness and safety effects than ACDF. In the future, more high-quality RCTs are warranted to enhance this conclusion.

Abbreviations: ACDF = anterior cervical decompression and fusion, ACDR = anterior cervical artificial disc replacement, ASD = adjacent segment degeneration, CCT = clinical controlled trial, CI = confidence interval, DRAE = device-related adverse event, MCS = mental component summary, ND = neurological deterioration, NDI = neck disability index, OCS = overall clinical success, PCS =

The authors declare that National "Twelfth Five-Year" Plan for Science and Technology Support (2012BAI18B05) was received for this meta-analysis. The Manuscript submitted does not contain information about medical device(s)/drug(s). No benefits in any form have been or will be received from a commercial party related directly or indirectly to the subject of this manuscript.

The authors have no conflicts of interest to disclose.

Supplemental Digital Content is available for this article.

^a Department of Orthopedics III, Beijing University of Chinese Medicine, Dongzhimen Hospital, Beijing, ^b Department of Orthopedics, Bayannaoer City Hospital, Bayannaoer City, ^c School of Basic Medical Sciences, Beijing University of Chinese Medicine, ^d Department of Orthopedics, China-Japan Friendship Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China.

* Correspondence: Xing Yu, Beijing University of Chinese Medicine, Dongzhimen Hospital, Beijing 100700, China (e-mail: yuxingbucm@sina.com).

Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc.

This is an open access article distributed under the Creative Commons Attribution-NoDerivatives License 4.0, which allows for redistribution, commercial and noncommercial, as long as it is passed along unchanged and in whole, with credit to the author.

Medicine (2018) 97:13(e0005)

Received: 24 November 2017 / Received in final form: 1 February 2018 / Accepted: 2 February 2018 http://dx.doi.org/10.1097/MD.000000000010005

Editor: Giovanni Tarantino.

Xing Yu contributed to the design of the study. He Zhao and Li-Jun Duan were responsible for data collection, data analysis, and drafting the manuscript. Yu-Shan Gao, Yong-Dong Yang, Ding-Yan Zhao, and Xiang-Sheng Tang contributed to analyzing the data with regard to its potential clinical significance. Yang Xiong, Zhen-Guo Hu, and Chuan-Hong Li conceived the meta-analysis and participated in its design and coordination. Xing Yu, He Zhao, and Li-Jun Duan screened titles and abstracts of eligible citations and determined if they met the inclusion criteria to this meta-analysis. All authors read and approved the final manuscript. All those who contributed to this meta-analysis meet the criteria for authorship and have been listed as authors.

physical component summary, PS = patient satisfaction, RCT = randomized controlled trial, RR = risk ratio, SF-12 = Short Form 12, SMD = standard mean difference, SSI = subsequent surgical intervention, VAS = visual analog scale.

Keywords: anterior cervical artificial disc replacement, anterior cervical decompression and fusion, bi-level cervical spondylosis, follow-up, meta-analysis

1. Introduction

According to a recent public health report, the Global Burden of Disease Study, neck pain is the main cause of movement disorders, with current estimates of 349 million people affected worldwide.^[1] This large number of patients will continue to increase further. A previous review of the literature, described neck pain as a chronic condition associated with intervertebral disc degeneration.^[2,3] Current conservative treatment includes use of nonsteroidal anti-inflammatory drugs at earlier stages, but invasive interventions are standard treatments at later stages.^[4]

Since the 1950s, anterior cervical decompression and fusion (ACDF) has been regarded as the "gold standard" of surgical therapy for symptomatic cervical myelopathy or radiculopathy, achieving neural decompression, segmental stabilization, and favorable results in clinical follow-up.^[5-7] However, ACDF is associated with pseudarthrosis formation, limitation of index level, and accelerated adjacent segment degeneration (ASD).^[8,9] Thus, anterior cervical artificial disc replacement (ACDR) represents a new, relative segmental motion-preserving procedure for cervical spondylosis. Compared with ACDF, ACDR can restore the interspace height of cervical vertebra, preserve the index/adjacent level, and also theoretically prevent ASD.^[10,11] Each procedure has its own characteristic features, and most studies have compared single-level ACDR with ACDF, but the safety and efficacy of bi-level procedure remains controversial. To provide a high level of evidence for decision making by clinicians and patients, we performed a meta-analysis to compare outcomes after bi-level ACDR with those of bi-level ACDF, to evaluate which procedure yields more favorable patients.

2. Materials and methods

2.1. Search strategy

To search all of the relevant literature, we systematically searched literature published in the database (PubMed, Embase, Web of Science, and Cochrane Central Register of Controlled Trials). Search terms were subjected to the following: "anterior cervical artificial disc replacement," "cervical total disc replacement," "cervical artificial disc," "disc arthroplasty," ACDR, CTDA, CDA, "anterior cervical decompression and fusion," "anterior interbody fusion," ACDF, "2 level," "two level," "bi-level," "double level" with various combinations of the operators "AND," "NOT," and "OR." There were restriction of study design was controlled trial published between January 1, 2000 and July 1, 2017. Restriction of languages was English. References cited in the relevant articles were also reviewed (see in Supplement 1, http://links.lww.com/MD/C171).

2.2. Inclusion criteria

All studies on treatment of bi-level cervical spondylosis were reviewed. The criteria for inclusion of an article were ACDR compared with ACDF for treatment of 2-level cervical spondylosis; patients were 18 years old or greater; patients were diagnosed (computed tomography, magnetic resonance imaging, or plain radiographs) with symptomatic cervical degenerative disc disease in bi-level between C-1 to C-7; unresponsive to nonoperative: conservative treatment for at least 6 weeks or presence of progressive symptoms or signs of nerve root/spinal cord compression; physically and mentally able and willing to comply the protocol; and studies with follow-up more than 12 months (Table 1).

Table 1

Quality assessment of included RCT studies by using the Furlan scores.

Criteria	Cheng et al	Jawahar et al	Grob et al	Coric et al	Davis et al	Radcliff et al	Jackson and Johnson	Gornet et al	Lanman et al
(A) 1. Was the method of randomization adequate?	Unclear	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Unclear
(B) 2. Was the treatment allocation concealed?	Unclear	Yes	Unclear	Unclear	Yes	Yes	Unclear	Unclear	Unclear
(C) Was knowledge of the allocated interventions adequately prevented during the study?									
3. Was the patient blinded to the intervention?	Unclear	Yes	Unclear	Yes	Yes	Yes	Yes	Yes	Unclear
4. Was the care provider blinded to the intervention?	Unclear	No	Unclear	Unclear	No	No	Unclear	Yes	No
5. Was the outcome assessor blinded to the intervention?	Unclear	Unclear	Unclear	Unclear	No	No	Unclear	No	No
(D) Were incomplete outcome data adequately addressed?									
6. Was the drop-out rate described and acceptable?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
7. Were all randomized participants analyzed in the group to which they were allocated?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
(E) 8. Are reports of the study free of suggestion of selective outcome reporting? (F) Other sources of potential bias	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
9. Were the groups similar at baseline regarding the most important prognostic indicators?	Yes	Yes	Yes	Unclear	Yes	Yes	Unclear	Yes	Yes
10. Were cointerventions avoided or similar?	Yes	Yes	Yes	Unclear	Yes	Yes	Unclear	Yes	Yes
11. Was the compliance acceptable in all groups?	Yes	Yes	Yes	Unclear	Yes	Yes	Unclear	Yes	Yes
12. Was the timing of the outcome assessment similar in all group?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Scores	7	10	8	6	10	10	6	10	7

RCTs = randomized controlled trials.

Table 2

Inclusion and exclusion criteria for article selection.

	Inclusion criteria	Exclusion criteria
Patients	18 years old or older	<18 years old
Type of condition	ACDR compared with ACDF for treatment of 2-level cervical spondylosis	Not ACDR and ACDF treating bi-level cervical spondylosis
	Patients were 18 years old or greater	<18 years old
	Patients were diagnosed (CT, MRI, or plain radiographs) with symptomatic cervical degenerative disc disease in bi-level between C-1 to C-7	Single- or multilevel cervical spondylosis
	Unresponsive to nonoperative: conservative treatment for at least 6 wk or presence of progressive symptoms or signs of nerve root/spinal cord compression	The outcomes were graphic without numerical values
	Physically and mentally able and willing to comply the protocol	Neoplastic etiology, infection, traumatic fracture, Paget disease, osteomalacia, osteoporosis, active systemic infection of surgical site or history, rheumatoid arthritis, other autoimmune disease or any other metabolic bone disease
	Studies with follow-up more than 12 mo	Metal sensitivity or mental diseases
		Studies with follow-up <12 mo
		Case report, review article, meta-analysis, the same data had been published previously
		Basic medical research (cell or animal experiment)
Treatment	Bi-levels ACDR vs. ACDF	Not included ACDR vs. ACDF
Publication data	Published between January 2000 and July 2017	Published before 2000
Language Design	English Not limited	Non-English

ACDF = anterior cervical decompression and fusion, ACDR = anterior cervical artificial disc replacement, CT = computed tomography, MRI = magnetic resonance imaging.

2.3. Exclusion criteria

Patients were excluded if they were associated with: not ACDR and ACDF treating bi-level cervical spondylosis; <18 years old; single- or multilevel cervical spondylosis; the outcomes were graphic without numerical values; neoplastic etiology, infection, traumatic fracture, Paget disease, osteomalacia, osteoporosis, active systemic infection of surgical site or history, rheumatoid arthritis, other autoimmune disease or any other metabolic bone disease; metal sensitivity or mental diseases; studies with followup <12 months; case report, review article, meta-analysis, the same data had been published previously; and basic medical research (cell or animal experiment) (Table 2).

2.4. Data extraction

The following data were extracted by 2 authors independently using a purpose-designed form: first author and year, study design, region, details, intervention, follow-up (months), and outcomes. Disagreement between the 2 reviewers was arbitrated by the third reviewer. If any disagreements existed, a third author was consulted to discussion until consensus was reached. The outcome including at least one of the following outcomes (Table 2):

- 1. NDI (neck disability index)
- 2. VAS (visual analog scale) neck
- 3. VAS arm
- 4. SF-12 (Short Form 12) MCS (mental component summary)
- 5. SF-12 (Short Form 12) PCS (physical component summary)
- 6. OCS (overall clinical success)
- 7. PS (patient satisfaction)
- 8. DRAE (device-related adverse event)
- 9. SSI (subsequent surgical intervention)
- 10. ND (neurological deterioration)
- 11. ASD (adjacent segment degeneration)

2.5. Quality assessment

The quality of the studies was independently assessed by the 2 authors according to The checklist by Furlan et al^[12,13] was used to evaluate the methodological quality of randomized controlled trials (RCTs). Evaluation of clinical controlled studies was performed with the MINORS scale. Every study was assessed by 2 independent researchers and judgment of every item. Any disagreement with respect to eligibility during the extraction was discussed and resolved.


2.6. Statistical analysis

The risk ratio (RR) and the corresponding 95% confidence interval (CI) were assessed for the dichotomous outcomes, and the standardized mean difference (SMD) and 95% CI were assessed for the continuous outcomes. The chi-squared test and Higgin I^2 test were used to evaluate the heterogeneity. A P value <.10 for the chi-squared test or I² values exceeding 50% indicated substantial heterogeneity. A fixed-effect model was used if significantly statistical heterogeneity was absent; otherwise, a random-effect model was applied. Sensitivity analysis was performed to detect the influence of a single study on the overall estimate via omitting 1 study in turn when necessary. Owing to the limited number (11) of included studies, publication bias was not assessed. P < .05 in 2-tailed tests was considered statistically significant. A meta-analysis was performed on the extracted data with RevMan 5.0 software (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark).

3. Results

3.1. Search results

Flow chart for inclusion of studies is shown in Fig. 1. The literature search initially yielded 325 relevant trials from PubMed



(N=47), Embase (N=113), Web of Science (N=3), and The Cochrane Library (N=162). After we reviewed the titles and abstracts of all trials, 128 trials were excluded. We continued to refine and exclude the 197 studies, 21 potentially studies were obtained, then 10 studies were excluded due to fail to meet criteria. Finally, 9 RCTs and 2 clinical controlled trials (CCTs) containing 2715 patients were included for this meta-analysis. We recorded the characteristics of the 11 included trials, as well as the details of the clinical outcome measurement (Table 3).

3.2. Quality assessment

The Furlan scores in 9 RCTs were in the range from 6 to 10 of 12 (Table 1). Seven RCTs were scored 7 or higher, and 2 RCTs were scored lower than 7, suggesting overall high quality of studies. The MINORS scale of studies in both studies was 17 and 18 and judged as good quality (Table 4). They were considered high methodological quality.

3.3. Clinical effectiveness

Seven studies provided NDI score. There was significant difference in the NDI score between 2 groups. The overall effect showed that the ACDR group had statistically higher NDI scores improvement than the ACDF group (SMD=0.41 [0.29, 0.52], P < .00001, Fig. 2). Similarly, 7 studies with pooled results indicated that the ACDR group had statistically higher VAS

scores in neck pain improvement than the ACDF group. VAS neck pain (SMD = 0.69 [0.34, 1.04], P = .0001, Fig. 3). However, there is no significant difference between 2 groups in VAS arm pain (SMD=0.36 [-0.01, 0.73], P=.06, Fig. 3). Two studies and 3 studies provided SF-12 MCS and PCS score, respectively. The pooled results indicate that there was no significant difference in the MCS score between 2 groups (SMD=0.13 [-0.08, 0.34], P=.21, Fig. 4). The pooled PCS score showed significant difference between the ACDR and ACDF group (SMD=0.38 [0.22, 0.53], P < .00001, Fig. 4). There were 6 studies provided OCS, the pooled result showed that ACDR group is superior to ACDF group (SMD = 1.49 [1.20, 1.85], P = .0003, Fig. 5). PS was also reported in 5 studies, the overall effect showed that ACDR group had statistically higher rate improvement than the ACDF group (SMD=1.06 [1.03, 1.09], P=.0003, Fig. 6), and 2 studies reported that one who experienced operation would also recommend their treatment to friends (SMD=1.12 [1.05, 1.19], P = .0002, Fig. 6).

3.4. Clinical safety

Six studies reported DRAE. Patients in the ACDR group had statistically significant lower incidence of DRAE (RR=0.59 [0.48, 0.73], P < .0001, Fig. 7). There was significantly more SSI rate extracted in 7 studies in the ACDF group than in the ACDR group (RR=0.29 [0.21, 0.39], P < .00001, Fig. 8). However, ND rate also indicates that there was no statistically significant

Table 3

Characteristics of included studies.

First author and year	Study design	Region	Details	Intervention	Follow-up, mo	Outcomes
Kim et al ^[14] 2009	Prospective cohort	South Korea	n=40	Prosthetic type	ACDR:	1.2
	study		ACDR: 12	ACDR: Bryan Cervical Artificial Disc Prosthesis	18 (13–37)	
			ACDF: 28	(Medtronic Sofamor Danek, Memphis, TN) ACDF: Blackstone cage (Blackstone Medical	ACDF:	
			Mean age	lnc) Solis cage (Stryker Spine)	21 (14–38)	
			ACDR: 46.9 y (30-58)	ABC plate (Aesculap)	(
			ACDF: 52.7 y (30–78)	Atlantis plate (Medtronic, Sofamor Danek)		
			Gender ACDR: 8 males, 4 females	Types of cervical spondylosis ACDR: radiculopathy (n = 10) Myelopathy (n =		
			ACDF: 17 males, 11 females	2) ACDF: radiculopathy (n = 24) Myelopathy (n =		
			Follow-up rate	4) Index level		
				ACDR: C4-C5-C6 (n=4), C5-C6-C7 (n=8) ACDF: C4-C5-C6 (n=13), C5-C6-C7 (n=		
Cheng et al ^[15] 2009	Prospective	China	n=65	15) Prosthetic type	24	1.2.3.4.5
	randomized controlled trial					
			ACDR: 31	ACDR: Bryan Cervical Disc (Medtronic Sofamor Danek)		
			ACDF: 34	ACDF: ACDF with an iliac crest autograft and plate		
			Mean age	Types of cervical spondylosis		
			ACDR: 45 y ACDF: 47 y	All patients with radiculopathy or myelopathy Index level		
			Gender	From C3 to C7		
			ACDR: 16 males, 15 females			
			ACDF: 17 male, 17 females Follow-up rate			
			95.4%			
Jawahar et al ^[16]	Prospective	USA	n=22	Prosthetic type	37 (24-49)	1.2.6
	randomized controlled					
2010	FDA IDE trials		ACDR: 16	ACDR: Kineflex-C (SpinalMotion Inc., Mountain		
			ACDF: 6	View, CA), Mobi-C (LDR spine, Austin, TX) Advent Cervical Disc (Blackstone Inc.,		
			Moon ago	Parsippany, NJ)		
			Mean age ACDR: 45 y	ACDF: ACDF with cortical bone allograft Types of cervical spondylosis		
			ACDF: 47 y	All patients with radiculopathy or myelopathy		
			Gender	Index level		
			ACDR: 6 males, 10 females ACDF: 2 males, 4 females	From C3 to C7		
			Follow-up rate: not described			
Grob et al ^[17] 2010	Randomized	Switzerland	n=266	Prosthetic type	24	7.8.9
	controlled trials		ACDR: 58	ACDR: Bryan Cervical Disc (Medtronic Sofamor		
			ACDF: 208	Danek) Prestige II (Medronic Sofamor Danek)		
			Mean age	Discover (dePuy)		
			ACDR: 45.8±7.9	Prodisc-C (Synthes-Spine)		
			ACDF: 56.1 ± 10.8	ACDF: ACDF with autologous bone, allogenic bone, autogenic + allogenic, autogenic +		
				bone substitute, other/no fusion material,		
			Gender	other anterior stabilization, interbody cage		
				(Harms titanium cage [dePuy] or PEEK [Medtronic] cage), plates, cage + plates		
			ACDR: 27 males, 31 females	Types of cervical spondylosis		
			ACDF: 105 males, 103 females	Degenerative cervical spinal disease		
			Follow-up rate: 95%	Index level Not described		
Hou et al ^[18] 2014	Cohort study	China	n=120	Prosthetic type	ACDR:	1.2
	······································		ACDR: 32	ACDR: discover artificial cervical disc (DePuy	24.2 (13–27)	-
			ACDF: 88	Spine, Raynham, MA)	ACDF:	
			AUDE. 00	ACDF: ACDF with autogenous bone, different types of anterior cervical plates, standalone	AUDE.	
			Mean age	cages	23.3 (12–27)	
			ACDR: 46.3 y (30-69)	Types of cervical spondylosis	· · /	
			ACDF: 51.2 y (29–77) Gender	All patients with radiculopathy or myelopathy		
			ACDR: 20 males, 12 females	Index level ACDR: C3/C4-C5/C6 (n = 1), C4/C5-C5/C6 (n = 12)		
			ACDF: 38 males, 50 females	(n = 12) C5/C6-C6/C7 (n = 19)		
			Follow-up rate: 92.8%	ACDF: C4/C5–C5/C6 (n=40), C5/C6–C6/C7 (n=48)		

(continued)

Table 3 (continued).

First author and year	Study design	Region	Details	Intervention	Follow-up, mo	Outcomes
Coric et al ^[19] 2015	Prospective randomized controlled	USA	n=330	Prosthetic type	60	6.9
	FDA IDE trials		ACDR: 225	ACDR: Mobi-C cervical artificial disc		
			ACDF: 105	ACDF: ACDF		
			Mean age: not described Gender: not described	Types of cervical spondylosis Symptomatic cervical degenerative disc disease		
			Follow-up rate: 90.8%	Index level: not described		
Davis et al ^[20] 2015	Prospective	USA	n=330	Prosthetic type	48	1.2.3.4.5
	randomized controlled					
	FDA IDE trials		ACDR: 225	ACDR: Mobi-C cervical artificial disc (LDR		6.7.8.9.10
				Medical; Troyes, France)		
			ACDF: 105	ACDF: ACDF with corticocancellous allograft + anterior cervical plate		
			Mean age	Types of cervical spondylosis		
			ACDR: 45.3 ± 8.1 y	Symptomatic cervical degenerative disc disease		
			ACDF: $46.2 \pm 8.0 \text{ y}$ Gender	Index level ACDR: C3–C7		
			ACDR: 113 males, 112 females	ACDF: C3–C7		
			ACDF: 45 males, 60 females			
D. J. 1997 . J. 1921] 004.0	D	1104	Follow-up rate: 86.5%	Decelled's trace	00	10050
Radcliff et al ^[21] 2016	Prospective randomized	USA	n=330	Prosthetic type	60	1.2.3.5.6
	controlled					
	FDA IDE trials		ACDR: 225	ACDR: Mobi-C cervical artificial disc (LDR		7.8.9.10
			ACDF: 105	Medical) ACDF: ACDF with corticocancellous allograft+		
			AGDI: 105	anterior cervical plate		
			Mean age	Types of cervical spondylosis		
			ACDR: 45.3 ± 8.10 y (27-67)	Symptomatic cervical degenerative disc disease		
			ACDF: 46.2±7.99 y (27–66) Gender	Index level ACDR: C3–C7		
			ACDR: 113 males, 112 females	ACDF: C3-C7		
			ACDF: 45 males, 60 females			
Jackson and Johnson ^[22] 2016	Prospective	USA	Follow-up rate: 89.4% n = 330	Prosthetic type: not described	84	2.8.9.10
	randomized controlled trials	USA	11 - 550	Hostifete type. Het described	04	2.0.3.10
			ACDR: 225	Types of cervical spondylosis		
			ACDF: 105	Symptomatic cervical degenerative disc disease		
			Mean age: not described Gender: not described	Index level: not described		
			Follow-up rate: not described			
Gornet et al ^[23] 2017	Prospective	USA	n=397	Prosthetic type	24	1.6.7.8.9
	randomized					
	controlled FDA IDE trials		ACDR: 209	ACDR: Prestige LP (Medtronic Inc.)		
	I DA IDE tildis		ACDF: 188	ACDF: ACDF with cortical ring allograft, Atlantis		
				anterior cervical plate (Medtronic Inc.) as		
			Maan aga	part of ACDF		
			Mean age ACDR: 47.1±8.3 y	Types of cervical spondylosis Symptomatic cervical degenerative disc disease		
			ACDF: 47.3 ± 7.7 y	Index level		
			Gender	ACDR: C3-C7		
			ACDR: 92 males, 117 females ACDF: 90 males, 98 females	ACDF: C3-C7		
			Follow-up rate: 90.4%			
Lanman et al ^[24] 2017	Prospective	USA	n=397	Prosthetic type	84	6.7.8.9.10
	randomized					
	controlled FDA IDE trials		ACDR: 209	ACDR: Prestige LP (Medtronic Inc.)		
	. Breibe unuo		ACDF: 188	ACDF: ACDF with cortical ring allograft, Atlantis		
			M	cervical plate system (Medtronic Inc.)		
			Mean age ACDR: 47.1±8.3 y (22.0–75.0)	Types of cervical spondylosis Symptomatic cervical degenerative disc disease		
			ACDF: 47.3 ± 7.7 y (25.0–69.0)	Index level		
			Gender	ACDR: C3 to C7		
			ACDR: 92 males, 117 females ACDF: 90 males, 98 females	ACDF: C3 to C7		

1. NDI (neck disability index); 2. VAS (visual analog scale) neck; 3. VAS arm; 4. SF-12 (Short Form 12) MCS (mental component summary); 5. SF-12 (Short Form 12) PCS (physical component summary); 6. OCS (overall clinical success); 7. PS (patient satisfaction); 8. DRAE (device-related adverse event); 9. SSI (subsequent surgical intervention); 10. ND (neurological deterioration); 11. ASD (adjacent segment degeneration).

ACDF = anterior cervical decompression and fusion, ACDR = anterior cervical artificial disc replacement.

Table 4

Methodological quality of the CCT studies by using MINORS scale.

Quality items	Kim et al	Hou et al
A clearly stated aim	2	2
Inclusion of consecutive patients	2	2
Prospective data collection	0	0
Endpoints appropriate to the aim of the study	2	2
Unbiased assessment of the study endpoint	1	1
A follow-up period appropriate to the aims of study	1	2
<5% loss to follow-up	2	1
Prospective calculation of the sample size	0	0
An adequate control group	1	2
Contemporary groups	2	2
Baseline equivalence of groups	2	2
Adequate statistical analyses	2	2
Total score	17	18

CCT = clinical controlled trial.

between 2 groups (RR=0.61 [0.36, 1.01], P=.06, Fig. 9). In addition, 2 studies showed that there were also significantly more superior and inferior ASD rate in the ACDF group compared with ACDR (RR=0.40 [0.35, 0.46], P<.00001, Fig. 10).


3.5. Sensitivity analysis

The sensitivity analysis was conducted to discover whether the lack of each study will change the pooled OR and SMD completely. After removing each, no original pooled results were significantly changed. It proves that the overall meta-analysis results were reliable.

4. Discussion

Through analysis of level 1 evidence from 9 prospective randomized well-controlled clinical trials and 2 high-quality cohort studies, it was demonstrated that ACDR is superior to ACDF. Both effectiveness and safety parameters were examined by using RevMan 5.3 software. Previously used indicators, including the NDI, VAS neck and arm pain, SF-12 MCS and PCS, OCS, and PS revealed that improvement with ACDR shown an advantage over ACDF. However, ND rate was not statistically different between the 2 groups. More recently used indicators, including device-related AE, subsequent surgical intervention (SSI), and ASD rate demonstrated a lower incidence rate for ACDR than for ACDF. Although a meta-analysis and an RCT offer level 1 evidence, a meta-analysis allows for pooling of results to obtain a quantitative and statistically significant

		ACDR			ACDF		S	d. Mean Difference	Std. Mean	Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI Year	IV, Fixe	ed. 95% Cl
Kim SW 2009	18.2	1.3	12	18.4	0.9	28	2.9%	-0.19 [-0.87, 0.49] 2009	· · · · · · · · · · · · · · · · · · ·	
Cheng L 2009	39	15.2	31	32	11.7	34	5.4%	0.51 [0.02, 1.01] 2009		
Jawahar A 2010	44.9	2.6	16	43	2.9	6	1.4%	0.68 [-0.28, 1.65] 2010	8	
Hou Y 2014	29.1	11.22	32	10.85	31.5	88	7.8%	0.66 [0.24, 1.07] 2014		
Davis RJ 2015	36.5	21.3	225	28.5	18.3	105	24.4%	0.39 [0.16, 0.62] 2015		
Gornet MF 2017	37.1	9.96	209	33.2	12.41	188	33.8%	0.35 [0.15, 0.55] 2015		
Radcliff KE 2016	37	20	225	28	18	105	24.2%	0.46 [0.23, 0.70] 2016		1000
Total (95% CI)			750			554	100.0%	0.41 [0.29, 0.52]		•
Heterogeneity: Chi ² =	5.44, df :	= 6 (P =	0.49);	$ ^2 = 0\%$						
Test for overall effect:	Z = 6.94	(P < 0.	00001)						-1 -0.5 ACDF	0 0.5 1 ACDR




		ACDR			ACDF		5	Std. Mean Difference		Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV. Random, 95% CI
11.1.1 VAS neck										
Kim SW 2009	5.5	0.55	12	4.7	0.67	28	6.0%	1.23 [0.50, 1.96]	2009	
Cheng L 2009	5.8	0.6	31	4.5	0.7	34	7.2%	1.96 [1.36, 2.56]	2009	
Jawahar A 2010	61.7	3.5	16	61.6	4.1	6	4.5%	0.03 [-0.91, 0.96]	2010	
Hou Y 2014	5.5	0.6	32	5	0.6	88	9.0%	0.83 [0.41, 1.25]	2014	
Davis RJ 2015	53	30	225	48	29	105	10.9%	0.17 [-0.06, 0.40]	2015	-
Jackson R 2016	52.54	16.12	225	44.86	15.8	105	10.9%	0.48 [0.24, 0.71]	2016	-
Radcliff KE 2016	52.58	15.66	225	46.11	17.72	105	10.9%	0.40 [0.16, 0.63]	2016	-
Subtotal (95% CI)			766			471	59.5%	0.69 [0.34, 1.04]		•
Heterogeneity: Tau ² =	0.17; Ch	ni ² = 38.	61, df =	= 6 (P <	0.0000	1); $ ^2 = 1$	84%			
Test for overall effect:	Z = 3.82	(P=0.	0001)							
11.1.2 VAS arm										
Cheng L 2009	5.7	1.1	31	4.5	0.8	34	7.8%	1.24 [0.71, 1.78]	2009	
Davis RJ 2015	56	31	225	53	31	105	10.9%	0.10 [-0.14, 0.33]	2015	+
Radcliff KE 2016	56.88	15.05	225	50.54	16.47	105	10.9%	0.41 [0.17, 0.64]	2016	-
Jackson R 2016	53.54	14.86	225	53.94	17.26	105	10.9%	-0.03 [-0.26, 0.21]	2016	+.
Subtotal (95% CI)			706			349	40.5%	0.36 [-0.01, 0.73]		•
Heterogeneity: Tau ² =	0.12; Ch	ni² = 21.	94, df =	= 3 (P <	0.0001); l ² = 8	6%			
Test for overall effect:	Z = 1.90	(P = 0.	06)							
			1472			820	100.0%	0.55 [0.30, 0.81]		•
Total (95% CI)							0501		-+	
Total (95% CI) Heterogeneity: Tau ² =	0.14: Ch	$ni^2 = 68$.	18. df =	= 10 (P •	< 0.000	01): I ² =	85%			4 -2 0 2 4

Figure 3. The standardized mean difference estimate for the visual analog scale neck and arm pain.

	A	CDR		1	ACDF		S	td. Mean Difference		Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% Cl	Year	IV. Fixed, 95% CI
6.1.1 SF-12 MCS										
Cheng L 2009	15	12	31	11	10	34	6.5%	0.36 [-0.13, 0.85]	2009	
Davis RJ 2015	11	12	225	10	12	105	29.3%	0.08 [-0.15, 0.31]	2015	
Subtotal (95% CI)			256			139	35.8%	0.13 [-0.08, 0.34]		-
Heterogeneity: Chi ² = 0	0.99, df :	= 1 (P	= 0.32)	; 12 = 09	6					
Test for overall effect:	Z = 1.25	(P=(0.21)							
6.1.2 SF-12 PCS										
Cheng L 2009	15	10	31	11	11	34	6.5%	0.38 [-0.12, 0.87]	2009	
Davis RJ 2015	13	12	225	10	12	105	29.1%	0.25 [0.02, 0.48]	2015	
Radcliff KE 2016	13.4	7.18	225	9.68	7.66	105	28.5%	0.51 [0.27, 0.74]	2016	
Subtotal (95% CI)			481			244	64.2%	0.38 [0.22, 0.53]		•
Heterogeneity: Chi ² = 2	2.32, df =	= 2 (P	= 0.31)	; $ ^2 = 14$	%					
Test for overall effect:	Z = 4.71	(P < (0.00001	1)						
Total (95% CI)			737			383	100.0%	0.29 [0.16, 0.41]		•
Heterogeneity: Chi ² = 6	6.62, df =	= 4 (P	= 0.16)	; $I^2 = 40$	1%					
Test for overall effect:	Z = 4.52	(P < (0.00001	1)						-1 -0.5 0 0.5 1 ACDF ACDR
Test for subgroup diffe	rences:	Chi ² =	3.31. 0	f = 1 (P	= 0.0	7), $ ^2 =$	69.8%			ACDP ACDR


Figure 4. The standardized mean difference estimate for the Short Form 12 mental component summary and physical component summary.

	ACD	R	ACD	F		Risk Ratio			Ris	sk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H. Random, 95% Cl	Year		M-H. Ra	ndom, 95% Cl	
Lanman TH 2017	164	209	118	188	21.5%	1.25 [1.10, 1.43]				-	
Jawahar A 2010	11	16	4	6	7.4%	1.03 [0.54, 1.99]	2010		-	-	
Gornet MF 2017	170	209	130	188	21.9%	1.18 [1.05, 1.32]	2015			-	
Davis RJ 2015	149	225	38	105	17.1%	1.83 [1.40, 2.40]	2015			_	
Coric D 2015	137	225	33	105	16.1%	1.94 [1.43, 2.62]	2015				
Radcliff KE 2016	137	225	33	105	16.1%	1.94 [1.43, 2.62]	2016				
Total (95% CI)		1109		697	100.0%	1.49 [1.20, 1.85]				•	
Total events	768		356								
Heterogeneity: Tau ² =	0.05; Chi ²	= 28.2	8, df = 5 (P < 0.0	0001); l ² =	82%		00	0.5		1 E
Test for overall effect:	Z = 3.64 (P = 0.0	003)					0.2	0.5 ACD	F ACDR	5



	ACD	R	ACD	F		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	Year	M-H, Fixed, 95% Cl
7.2.1 PS self					Sec. 1			
Lanman TH 2017	198	209	174	188	19.5%	1.02 [0.97, 1.08]		
Grob D 2010	54	58	187	208	8.7%	1.04 [0.95, 1.13]	2009	
Gornet MF 2017	198	209	168	188	18.8%	1.06 [1.00, 1.12]	2015	
Davis RJ 2015	217	225	93	105	13.5%	1.09 [1.01, 1.17]	2015	
Radcliff KE 2016	217	225	94	105	13.6%	1.08 [1.00, 1.16]	2016	
Subtotal (95% CI)		926		794	74.1%	1.06 [1.03, 1.09]		•
Total events	884		716					
Heterogeneity: Chi ² = 2	2.62, df =	4 (P = 0).62); l ² =	0%				
Test for overall effect:	Z = 3.67 (P = 0.0	002)					
7.2.2 PS others								
Davis RJ 2015	216	225	91	105	13.2%	1.11 [1.02, 1.20]	2015	
Radcliff KE 2016	213	225	88	105	12.8%	1.13 [1.03, 1.24]	2016	
Subtotal (95% CI)		450		210	25.9%	1.12 [1.05, 1.19]		-
Total events	429		179					· · · · · · · · · · · · · · · · · · ·
Heterogeneity: Chi ² =	0.10, df =	1 (P = ().75); l ² =	0%				
Test for overall effect:	Z = 3.67 (P = 0.0	002)					
Total (95% CI)		1376		1004	100.0%	1.07 [1.04, 1.10]		•
Total events	1313		895					
Heterogeneity: Chi ² =	6.04, df =	6 (P = 0).42); l ² =	1%				0.7 0.85 1 1.2 1.5
Test for overall effect:	Z = 5.13 (P < 0.0	0001)					0.7 0.85 1 1.2 1.5 ACDF ACDR
Test for subgroup diffe								ACOP ACOR

Figure 6. The risk ratio estimate for the patient satisfaction rate.




estimate of treatment effects and the ability to draw more convincing conclusions.

Patient treated with ACDR showed greater NDI improvement than those treated with ACDF in follow-up. This result is consistent with single- or multilevel cervical treatment.^[24–26] We surmise that neck vertebrae can sustain a more favorable physical structure after an ACDR procedure compared with ACDF. The VAS score data for neck and arm pain, and the SF-12, for clinical effectiveness assessment, were also analyzed. The overall effect on neck pain showed that ACDR has favorable outcomes, possibly as a result of preservation of mobility and restoration of the neck muscles. However, some previous studies reported that there was no difference in clinical outcome between 2 types of operation in midterm follow-up.^[27] We speculate that the discrepancy was due to different standards for inclusion criteria and statistical methods. Similarly, although VAS neck pain improvement with ACDR was superior to that with ACDF, we performed subgroup analysis and found that there was no difference between the 2 groups in VAS arm pain. Unlike neck pain, we know that improvement in arm pain after surgical treatment depends on the degree of nerve root decompression that is vital guarantee for surgical effectiveness, which may else interpret why there is no statistical difference in neurological success. To determine whether different prostheses result in different outcomes between the 2 surgeries strategy, we conducted subgroup analysis. The result showed that ACDR is as effective as ACDF. Different from previous reports, ^[24,26] on the SF-12 PCS, ACDR is showed more positive results than ACDF. Interestingly, SF-12 MCS showed no statistical difference.

Whether ACDR or ACDF could reduce the incidence rate of ASD has remained controversial.^[28] Based on current understanding, ACDR cannot completely prevent the occurrence of ASD, but it can alleviate ASD by maintaining the mobility of the

	ACD	R	ACD	F		Risk Ratio		Risk Ra	tio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI Yea	ar	M-H. Fixed.	95% CI	
Lanman TH 2017	9	209	28	188	20.1%	0.29 [0.14, 0.60]				
Grob D 2010	0	58	7	208	2.3%	0.24 [0.01, 4.07] 200	9 -			
Davis RJ 2015	9	225	16	105	14.9%	0.26 [0.12, 0.57] 201	5			
Gornet MF 2017	5	209	15	188	10.8%	0.30 [0.11, 0.81] 201	5			
Coric D 2015	9	225	17	105	15.8%	0.25 [0.11, 0.54] 201	5			
Radcliff KE 2016	16	225	22	105	20.4%	0.34 [0.19, 0.62] 201	6			
Jackson R 2016	11	225	17	105	15.8%	0.30 [0.15, 0.62] 201	6			
Total (95% CI)		1376		1004	100.0%	0.29 [0.21, 0.39]		•		
Total events	59		122							
Heterogeneity: Chi ² =	0.52, df =	6 (P = 1	1.00); l ² =	0%			0.002		10	500
Test for overall effect:	Z = 7.97 (P < 0.0	0001)				0.002	0.1 1 ACDR A	10 CDF	500



	ACD	R	ACD	F		Risk Ratio			Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H. Random, 95% CI	Year		M-H. Random, 95% Cl	
Lanman TH 2017	18	209	34	188	28.9%	0.48 [0.28, 0.81]				
Davis RJ 2015	14	225	8	105	19.9%	0.82 [0.35, 1.89]	2015			
Jackson R 2016	30	225	36	105	32.7%	0.39 [0.25, 0.60]	2016		-	
Radcliff KE 2016	18	225	6	105	18.5%	1.40 [0.57, 3.42]	2016		-	
Total (95% CI)		884		503	100.0%	0.61 [0.36, 1.01]			•	
Total events	80		84							
Heterogeneity: Tau ² =	0.16; Chi ²	= 7.82	, df = 3 (F	P = 0.05	5); l ² = 62%	0		-		1000
Test for overall effect:								0.001	0.1 1 10 ACDR ACDF	1000

Figure 9. The risk ratio estimate for the neurological deterioration.

	ACDR		ACDF		Risk Ratio			Risk Ratio						
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	Year		M-H. Fixed. 95%					
10.1.1 superior														
Davis RJ 2015	62	225	68	105	26.3%	0.43 [0.33, 0.55]	2015			-				
Radcliff KE 2016	73	225	74	105	28.6%	0.46 [0.37, 0.58]	2016			-				
Subtotal (95% CI)		450		210	54.8%	0.44 [0.37, 0.53]				•				
Total events	135		142											
Heterogeneity: Chi ² = 0	0.21, df =	1 (P = (0.65); l ² =	0%										
Test for overall effect:	Z = 9.42 (P < 0.0	0001)											
10.1.2 inferior														
Davis RJ 2015	37	225	59	105	22.8%	0.29 [0.21, 0.41]	2015		_	-				
Radcliff KE 2016	50	225	58	105	22.4%	0.40 [0.30, 0.54]	2016			-				
Subtotal (95% CI)		450		210	45.2%	0.35 [0.28, 0.43]				•				
Total events	87		117											
Heterogeneity: Chi ² = '	1.91, df =	1 (P = 0	0.17); l ² =	48%										
Test for overall effect:	Z = 9.26 (P < 0.0	0001)											
Total (95% CI)		900		420	100.0%	0.40 [0.35, 0.46]				•				
Total events	222		259											
Heterogeneity: Chi ² = 4	4.97, df =	3 (P = 0	0.17); l ² =	40%				0.1	0.2	0.5	+	2	5	10
Test for overall effect:	Z = 13.23	(P < 0.	00001)					0.1	0.2			-	5	10
Test for subgroup diffe	rences: C	hi ² = 2.	94, df = 1	(P = 0	.09), l ² = 6	6.0%				ACI	JR AU	UF		
	Fig	ure 10.	The risk	c ratio e	estimate fo	or the adjacent-segm	nent dis	sc de	generat	ion rate.				

index level and relieving the intradiscal pressure in adjacent segment discs. On the one hand, Goffin et al^[29] reported that the intradiscal pressure in the adjacent segment in 2-level ACDR was clearly lower than that for ACDF, causing lower degeneration rate in adjacent levels. However, other spine surgeon found that multifusion induces ASD more extensively. Hilibrand^[30] reported that ASD outcomes in multilevel ACDF were inferior to those with single-level ACDF, the possible explanation is the fusion of degenerated or potentially degenerated segments during the operation. Conversely, in contrast to the doctrine of biomechanics, other authors believe that natural degeneration is the main cause of ASD.^[31] Although this is somewhat reasonable, some still believe that the physiological environment of the neck will inevitably be changed after surgery, apart from genetic predisposition,^[32] compared with ACDR, which preserves mobility, and flexibility, and is closer to a normal anatomic state, a fusion procedure changes the mechanical environment and adds to compensatory movement of the adjacent level, with both factors exacerbating ASD. Therefore, we speculate that there are 2 reasons for the high ASD rate in ACDF. First, the 2 pathological changes mentioned above lead to higher intradiscal pressure compared with that in ACDR, thus stimulating abundant inflammatory mediators in the adjacent disc. Second, the dominant inflammatory cytokines, such as interleukin-1 β and tumor necrosis factor- α ,^[33,34] contribute significantly to ASD. Together, the main causes of ASD are based on natural degeneration and surgical intervention. Although ACDR has advantages over ACDF with regard to ASD development, the greater significance maintaining the range of motion and restoring neck function. Another focus of attention is the apparent correlation between reoperation rate and ASD.^[35] In our study, we observed that SSI rate occurs more often with ACDF than ACDR. However, not all ASD requires reoperation, and vice versa. In addition, the author encounters a notable case in clinical, in which vertebrae between 2 prostheses developed a compression fracture resulting from excessive physiological load. Interestingly, no database search found a similar case report or study.

There are several limitations and merits of this study. First, only 11 studies were included in this study, the full text was

available for 9, and the others were articles from conference proceeding. This may lead to bias due to missing data. Second, although our electronic and manual search encompassed a range of databases, we only included articles published in English, it may lead language bias. At last, some of RCTs with incomplete data may decrease the quality of evidence and strength of analysis. Although, limitations in this research, there were some merits existed. First, our up-to-date article retrieval yielded 11 eligible studies including 9 RCTs (evidence of level 1) and 2 CCTs (evidence of level 2), it provided more high-level literature from origin and generated more credible results by evidence-based medicine analysis. Moreover, 5 multicenter RCTs under the guidance of FDA out of 9 RCTs may further reinforce the quality of the evidence. Finally, more high-quality RCTs with large sample size are required to investigate the efficiency of ACDR compared with ACDF.

5. Conclusion

Although there was no significant difference between ACDR and ACDF in ND, VAS arm MCS score, most effective indices such as NDI, VAS neck, PCS score, PS, OCS, is superior to ACDR than ACDF. In addition, safety indices of ACDR including DRAE, ASD, and SSI were better than ACDF. In all, ACDR appears to be more effective and safety than ACDF; however, more welldesigned studies with large samples are needed to provide further evidence for the effect and reliability of ACDR compared with ACDF in the treatment of cervical spondylosis.

Author contributions

Conceptualization: Y. Xiong. Data curation: Y-D. Yang, Z.-G. Hu. Investigation: D-Y. Zhao, L-J. Duan. Methodology: X-S. Tang, Y-S. Gao. Resources: C-H. Li. Supervision: X. Yu. Writing – original draft: H. Zhao.

References

- [1] Vos T, Ryan MB, Brad B, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;386: 743–800.
- [2] Baptiste DC, Fehlings MG. Pathophysiology of cervical myelopathy. Spine J 2006;6(suppl):190–7.
- [3] Shedid D, Benzel EC. Cervical spondylosis anatomy: pathophysiology and biomechanics. Neurosurgery 2007;60(supp 11):S7–13.
- [4] May M. Regenerative medicine: rebuilding the backbone. Nature 2013;503:S7–9.
- [5] Clements DH, O'Leary PF. Anterior cervical discectomy and fusion. Spine (Phila Pa 1976) 1990;15:1023-5.
- [6] Gore DR, Sepic SB. Anterior discectomy and fusion for painful cervical disc disease: a report of 50 patients with an average follow-up of 21 years. Spine (Phila Pa 1976) 1998;23:2047–51.
- [7] Yue WM, Brodner W, Highland TR. Long-term results after anterior cervical discectomy and fusion with allograft and plating: a 5-to 11-year radiologic and clinical follow-up study. Spine (Phila Pa 1976) 2005;30:2138–44.
- [8] Matsumoto M, Okada E, Ichihara D, et al. Anterior cervical decompression and fusion accelerates adjacent segment degeneration: comparison with asymptomatic volunteers in a ten-year magnetic resonance imaging follow-up study. Spine (Phila Pa 1976) 2010;35:36–43.
- [9] Nanda A, Sharma M, Sonig A, et al. Surgical complications of anterior cervical diskectomy and fusion for cervical degenerative disk disease: a single surgeon's experience of 1,576 patients. World Neurosurg 2014;82:1380–7.
- [10] Robertson JT, Papadopoulos SM, Traynelis VC. Assessment of adjacentsegment disease in patients treated with cervical fusion or arthroplasty: a prospective 2-year study. J Neurosurg Spine 2005;3:417–23.
- [11] Dmitriev AE, Cunningham BW, Hu N, et al. Adjacent level intradiscal pressure and segmental kinematics following a cervical total disc arthroplasty: an in vitro human cadaveric model. Spine (Phila Pa 1976) 2005;30:1165–72.
- [12] Furlan AD, Pennick V, Bombardier C, et al. 2009 Updated method guidelines for systematic reviews in the Cochrane Back Review Group. Spine (Phila Pa 1976) 2009;34:1929–41.
- [13] Van Tulder M, Furlan A, Bombardier C, et al. Updated method guidelines for systematic reviews in the Cochrane Collaboration Back Review Group. Spine (Phila Pa 1976) 2003;28:1290–9.
- [14] Kim SW, Limson MA, Kim SB, et al. Comparison of radiographic changes after ACDF versus Bryan disc arthroplasty in single and bi-level cases. Eur Spine J 2009;18:218–31.
- [15] Cheng L, Nie L, Zhang L, et al. Fusion versus Bryan cervical disc in twolevel cervical disc disease: a prospective, randomised study. Int Orthop 2009;33:1347–51.
- [16] Jawahar A, Cavanaugh DA, Kerr EJ, et al. Total disc arthroplasty does not affect the incidence of adjacent segment degeneration in cervical spine: results of 93 patients in three prospective randomized clinical trials. Spine J 2010;10:1043–8.
- [17] Grob D, Porchet F, Kleinstück FS, et al. A comparison of outcomes of cervical disc arthroplasty and fusion in everyday clinical practice: surgical and methodological aspects. Eur Spine J 2010;19:297–306.
- [18] Hou Y, Liu Y, Yuan W, et al. Cervical kinematics and radiological changes after discover artificial disc replacement versus fusion. Spine J 2014;14:867–77.

- [19] Coric D, Albert T, Radcliff K. Five-year results of 2-level cervical total disc replacement compared with anterior discectomy and fusion: an independent review of a prospective, randomized, controlled multicenter investigational device exemption clinical trial. Clin Neurosurg 2015;62: 221–2.
- [20] Davis RJ, Nunley PD, Kim KD, et al. Two-level total disc replacement with Mobi-C cervical artificial disc versus anterior discectomy and fusion: a prospective, randomized, controlled multicenter clinical trial with 4-year follow-up results. J Neurosurg Spine 2015;22:15–25.
- [21] Radcliff K, Coric D, Albert T. Five-year clinical results of cervical total disc replacement compared with anterior discectomy and fusion for treatment of 2-level symptomatic degenerative disc disease: a prospective, randomized, controlled, multicenter investigational device exemption clinical trial. J Neurosurg Spine 2016;25:213–324.
- [22] Jackson R, Johnson DE. Neurological outcomes of two-level total disk replacement versus anterior discectomy and fusion: 7-year results from a prospective, randomized, multicenter trial. Neurosurgery 2016;63(suppl 1):164.
- [23] Gornet MF, Lanman TH, Burkus JK, et al. Cervical disc arthroplasty with the Prestige LP disc versus anterior cervical discectomy and fusion, at 2 levels: results of a prospective, multicenter randomized controlled clinical trial at 24 months. J Neurosurg Spine 2017;26:653–67.
- [24] Lanman TH, Burkus JK, Dryer RG, et al. Long-term clinical and radiographic outcomes of the Prestige LP artificial cervical disc replacement at 2 levels: results from a prospective randomized controlled clinical trial. J Neurosurg Spine 2017;27:7–19.
- [25] Zhang Y, Liang C, Tao Y, et al. Cervical total disc replacement is superior to anterior cervical decompression and fusion: a meta-analysis of prospective randomized controlled trials. PLoS ONE 2015;10: e0117826.
- [26] Nunley PD, Jawahar A, Kerr EJ, et al. Choice of plate may affect outcomes for single versus multilevel ACDF: results of a prospective randomized single-blind trial. Spine J 2009;9:121–7.
- [27] Mummaneni PV, Amin BY, Wu JC, et al. Cervical artificial disc replacement versus fusion in the cervical spine: a systematic review comparing long-term follow-up results from two FDA trials. Evid Based Spine Care J 2012;3:59–66.
- [28] Kepler CK, Brodt ED, Dettori JR, et al. Cervical artificial disc replacement versus fusion in the cervical spine: a systematic review comparing multilevel versus single-level surgery. Evid Based Spine Care J 2012;3:19–30.
- [29] Goffin J, Van Calenbergh F, van Loon J, et al. Intermediate follow-up after treatment of degenerative disc disease with the Bryan Cervical Disc Prosthesis: single-level and bi-level. Spine (Phila Pa 1976) 2003;28:2673–8.
- [30] Hilibrand AS, Carlson GD, Palumbo MA, et al. Radiculopathy and myelopathy at segments adjacent to the site of a previous anterior cervical arthrodesis. J Bone Joint Surg Am 1999;81:519–28.
- [31] Vernon-Roberts B, Moore RJ, Fraser RD. The natural history of agerelated disc degeneration: the pathology and sequelae of tears. Spine (Phila Pa 1976) 2007;32:2797–804.
- [32] Nouri A, Tetreault L, Singh A. Degenerative cervical myelopathy: epidemiology, genetics, and pathogenesis. Spine (Phila Pa 1976) 2015;40:E675–93.
- [33] Johnson ZI, Schoepflin ZR, Choi H, et al. Disc in flames: roles of TNF- α and IL-1 β in intervertebral disc degeneration. Eur Cell Mater 2015;30:104–16.
- [34] Risbud MV, Shapiro IM. Role of cytokines in intervertebral disc degeneration: pain and disc content. Nat Rev Rheumatol 2014;10:44–56.
- [35] Kepler CK, Hilibrand AS. Management of adjacent segment disease after cervical spinal fusion. Orthop Clin North Am 2012;43:53–62.